Pleiotropic roles of formyl peptide receptors

Cytokine and Growth Factor Reviews

Volumn 12, Issue 1, 2001, Pages 91-105

  Le, Yingying ^a   Oppenheim, Joost J ^a   Wang, Ji Ming ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Formyl peptide receptors; HIV 1; Signal transduction

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PROTEIN; CHEMOTACTIC PEPTIDE RECEPTOR; FORMYL PEPTIDE RECEPTOR; FORMYL PEPTIDE RECEPTOR LIKE 1; G PROTEIN COUPLED RECEPTOR; IMMUNOGLOBULIN RECEPTOR; LIGAND; LIPOCORTIN 1; PRION PROTEIN; RECEPTOR; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL; CHEMOTAXIS; DEGENERATIVE DISEASE; DESENSITIZATION; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFECTION RESISTANCE; INFLAMMATION; LEUKOCYTE ACTIVATION; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

AMYLOIDOSIS; ANIMALS; ANNEXIN A1; HIV INFECTIONS; HUMANS; LIGANDS; NEURODEGENERATIVE DISEASES; PHOSPHORYLATION; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, IMMUNOLOGIC; RECEPTORS, LIPOXIN; RECEPTORS, PEPTIDE; SIGNAL TRANSDUCTION;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0035066815     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(01)00003-X     Document Type: Review

References (147)

1. Chemoattractant stimulus-response coupling
2. Complement: Biologically active products
3. Specific receptors of platelet-activation factor, receptor heterogeneity, and signal transduction mechanisms
4. Properties of the novel pro-inflammatory supergene 'intercrine' cytokine family
5. Chemokines
6. Recent advances in chemokines and chemokine receptors
7. N-formylmethionyl peptides as chemoattractants for leucocytes
8. The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli
9. Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli
10. Chemoattractant receptor cross-desensitization
11. Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes
12. Activation of the chemotactic peptide receptor FPRL1 in monocytes phosphorylates the chemokine receptor CCR5 and attenuates cell responses to selected chemokines
13. The N-formyl peptide chemotactic receptors
14. The N-formyl peptide receptor: A model for the study of chemoattractant receptor structure and function
15. Cloning of the gene coding for the human receptor for formyl peptides: Characterization of a promoter region and evidence for polymorphic expression
16. Sequence and organization of the human N-formyl peptide receptor-encoding gene
17. Structure, 5′-flanking sequence, and chromosome location of the human N-formyl peptide receptor gene. A single-copy gene comprised of two exons on chromosome 19q.13.3 that yields two distinct transcripts by alternative polyadenylation
18. N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation
19. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines
20. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia
21. Expression of functional formyl peptide receptors by human astrocytoma cell lines
22. FMLP actions and its binding sites in isolated human coronary arteries
23. Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues, and cells
24. Molecular evolution of the N-formyl peptide and C5a receptors in non-human primates
25. Molecular cloning of the fMet-Leu-Phe receptor from neutrophils
26. The rabbit neutrophil N-formyl peptide receptor. cDNA cloning, expression, and structure/function implications
27. Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains
28. A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family
29. Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor
30. Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19
31. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA
32. The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors
33. Differential expression of members of the N-formylpeptide receptor gene cluster in human phagocytes
34. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release
35. Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse
36. N-formylpeptides induce two distinct concentration optima for mouse neutrophil chemotaxis by differential interaction with two N-formylpeptide receptor (FPR) subtypes: Molecular characterization of FPR2, a second mouse neutrophil FPR
37. A peptide with unique receptor specificity. Stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils
38. Distribution of the receptor for a novel peptide stimulating phosphoinositide hydrolysis in human leukocytes
39. Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus via phospholipase D activation in human monocytes
40. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation
41. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast
42. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor
43. T21/DP107, a synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G protein-coupled formyl peptide receptors
44. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes
45. A synthetic peptide derived from HIV-1 gp120 down-regulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the seven-transmembrane G protein-coupled receptor FPRL1/LXA4R
46. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils
47. A novel ligand of the formyl peptide receptor: Annexin I regulates neutrophil extravasation by interacting with the FPR
48. A seven-transmembrane, G-protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells
49. Amyloid β42 activates a G protein-coupled chemoattractant receptor FPR-like 1
50. The neurotoxic prion peptide fragment PrP106-126 is a chemotactic agonist for the g protein-coupled receptor fpr11
51. Activation of lipoxin A4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation
52. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells
53. Amyloid deposits and amyloidsis
54. Amyloidosis: A final common pathway for protein deposition in tissues
55. Translating cell biology into therapeutic advances in Alzheimer's disease
56. Neurotoxicity of a prion protein fragment
57. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor
58. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: Evidence for anti-inflammatory receptors
59. Further studies on the structural requirements for synthetic peptide chemoattractants
60. Formylpeptide receptor antagonists: Structure and activity
61. N-terminus urea-substituted chemotactic peptides: New potent agonists and antagonists toward the neutrophil fMLF receptor
62. Selective inhibition of N-formylpeptide-induced neutrophil activation by carbamate-modified peptide analogues
63. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation
64. Cyclosporin H is a potent and selective formyl peptide receptor antagonist. Comparison with N-t-butoxycarbonyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-leucyl-L- phenylalanine and cyclosporins A, B, C, D, and E
65. Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine
66. Characterization of chenodeoxycholic acid as an endogenous antagonist of the g-coupled formyl peptide receptors
67. Phagocytic cells: Stimulus-response coupling mechanismes
68. Differences in phosphorylation of formylpeptide and C5a chemoattractant receptors correlated with differences in desensitization
69. Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usage
70. Two distinct Gi-proteins mediate formyl peptide receptor signal transduction in human leukemia (HL-60) cells
71. Differential activation of dibutyryl cAMP-differentiated HL-60 human leukemia cells by chemoattractants
72. Quantitative analysis of formyl peptide receptor couping to Giα1, Giα2, and Giα3
73. Subsecond modulation of formyl peptide-linked guanine nucleotide-binding proteins by guanosine 5′-O-(3-thio)triphosphate in permeabilized neutrophils
74. Fixation traps formyl peptide receptors in high and low affinity forms that can be regulated by GTP[S] in the absence of ligand
75. Continuous spectrofluorometric analysis of formyl peptide receptor ternary complex interactions
76. Isozyme-selective stimulation of phospholipase C-β2 by G Protein βγ-subunits
77. Gbetagamma stimulates phosphoinositide 3-kinase-gamma by direct interaction with two domains of the catalytic p110 subunit
78. fMet-Leu-Phe stimulates proinflammatory cytokine gene expression in human peripheral blood monocytes: The role of phosphatidylinositol 3-kinase
79. Function of PI3Kγ in thymocyte development, T cell activation, and neutrophil migration
80. Roles of PLC-β2 and -β3 and PI3Kγ in chemoattractant-mediated signal transduction
81. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation
82. Stimulation of human neutrophils with fMLP induces tyrosine phosphorylation and activation of two distinct mitogen-activated protein kinase
83. Formyl peptide receptors are coupled to multiple mitogen-activated protein kinase cascades by distinct signal transduction pathways: Role in activation of reduced nicotinamide adenine dinucleotide oxidase
84. G protein-coupled chemoattractant receptors regulate lyn tyrosine kinase-Shc adapter protein signaling complexes
85. Differential coupling of the formyl peptide receptor to adenylate cyclase and phospholipase C by the pertussis toxin-insensitive Gz protein
86. High constitutive activity of the human formyl peptide receptor
87. Formyl peptide receptor chimeras define domains involved in ligand binding
88. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors
89. Identification of an N-formyl peptide receptor ligand binding domain by a gain-of-function approach
90. Human formyl peptide receptor function role of conserved and nonconserved charged residues
91. Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling. Mapping with receptor-derived peptides
92. Reconstitution of a physical complex between the N-formyl chemotactic peptide receptor and G protein. Inhibition by pertussis toxin-catalyzed ADP ribosylation
93. Extensive contact between Gi2 and N-formyl peptide receptor of human neutrophils: Mapping of binding sites using receptor-mimetic peptides
94. Domains of the human neutrophil N-formyl peptide receptor involved in G protein coupling
95. Binding of low affinity N-formyl peptide receptors to G protein. Characterization of a novel inactive receptor intermediate
96. The role of the third intracellular loop of the neutrophil N-formyl peptide receptor in G protein coupling
97. Identification of putative sites of interaction between the human formyl peptide receptor and G protein
98. G-protein-coupled receptor regulation: Role of G-protein-coupled receptor kinases and arrestins
99. Regulation of tyrosine kinase cascades by G-protein-coupled receptors
100. Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization
101. Agonist-dependent phosphorylation of N-formylpeptide and activation peptide from the fifth component of C (C5a) chemoattractant receptors in differentiated HL60 cells
102. Phosphorylation of the N-formyl peptide receptor carboxyl terminus by the G protein-coupled receptor kinase, GRK2
103. G protein-coupled receptor kinases
104. Multiple activation steps of the N-formyl peptide receptor
105. Desensitization of N-formylpeptide receptor-mediated activation is dependent upon receptor phosphorylation
106. Phosphorylation of the N-formyl peptide receptor is required for receptor internalization but not chemotaxis
107. Differential phosphorylation paradigms dictate desensitization and internalization of the N-formyl peptide receptor
108. Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved 'DRY' sequence
109. Cell type- and developmental stage-specific activation of NF-kappaB by fMet-Leu-Phe in myeloid cells
110. Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor
111. Neutralization of HIV-1: A paradox of humoral proportions
112. Decline of anti-DP107 antibody associated with clinical progression
113. HIV-1 gp41 is a potent inhibitor of chemoattractant receptor expression and function in monocytes
114. HIV-1 envelope gp120 inhibits monocyte response to chemokines through CD4 signal-dependent chemokine receptor down-regulation
115. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus
116. Chemokine-induced phosphorylation of CC chemokine receptor 5 (CCR5)
117. Molecular mechanism of desensitization of the chemokine receptor CCR-5: Receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor
118. Virus-induced neutrophil dysfunction: Role in the pathogenesis of bacterial infections
119. Defective polymorphonuclear leukocyte chemotaxis in homosexual men with persistent lymph node syndrome
120. Reduced expression of interleukin-8 receptors A and B on polymorphonuclear neutrophils from persons with human immunodeficiency virus type 1 disease and pulmonary tuberculosis
121. Impaired neutrophil function in patients with AIDS or AIDS-related complex: A comprehensive evaluation
122. Inflammation as a pathogenic mechanism in Alzheimer's disease
123. Inflammation and Alzheimer's disease
124. PKC and tyrosine kinase involvement in amyloid beta (25-35)-induced chemotaxis of microglia
125. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia
126. Activation of nuclear factor-kappa B by beta-amyloid peptides and interferon-gamma in murine microglia
127. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia
128. Antiinflammatory drugs and Alzheimer's disease
129. Risk of Alzheimer's disease and duration of NSAID use
130. Clinical trial of indomethacin in Alzheimer's disease
131. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
132. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging
133. Suppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds
134. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
135. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils
136. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease
137. Beta amyloid toxicity does not require RAGE protein
138. Elimination of the class A scavenger receptor does not affect amyloid plaque formation or neurodegeneration in transgenic mice expressing human amyloid protein precursors
139. Beta-amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent
140. Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines
141. Activation of microglial cells by PrP and beta-amyloid fragments raises intracellular calcium through L-type voltage sensitive calcium channels
142. 2+ in microglia activated by prion protein fragment
143. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins
144. Prions
145. The contribution of inflammation to acute and chronic neurodegeneration
146. Microglia and prion disease: A review
147. Early-onset familial Alzheimer disease with coexisting β-amyloid and prion pathology